What risks should be monitored in bipolar disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Risks to Monitor in Bipolar Disorder

Patients with bipolar disorder require systematic monitoring for medication-related metabolic complications, mood episode relapse, suicide risk, and cardiovascular mortality—which collectively reduce life expectancy by 12-14 years. 1, 2

Critical Medication-Related Risks

Metabolic Complications (Highest Priority)

Atypical antipsychotics cause significant weight gain, type 2 diabetes, and hyperlipidemia that directly increase cardiovascular mortality. 1

Required monitoring protocol:

  • Baseline: Body mass index (BMI), waist circumference, blood pressure, fasting glucose, fasting lipid panel
  • Follow-up: BMI monthly for 3 months, then quarterly; blood pressure, fasting glucose, and lipids at 3 months, then yearly 1

The metabolic syndrome prevalence reaches 37% in bipolar patients, with obesity at 21% and type 2 diabetes at 14%—all substantially higher than the general population 2. These complications occur early and aggressively, contributing to the 1.6-2 fold increase in cardiovascular mortality occurring a mean of 17 years earlier than the general population 2.

Lithium-Specific Toxicities

Before starting lithium, obtain: complete blood count, thyroid function tests, urinalysis, blood urea nitrogen, creatinine, serum calcium, and pregnancy test in females 1

Once stable, monitor every 3-6 months: lithium levels, renal function (BUN/creatinine), thyroid function (TSH), urinalysis 1

Lithium causes thyroid dysfunction and progressive renal impairment. Bradycardia, T-wave changes, and AV-block can occur, particularly with concomitant anti-arrhythmic drugs 3.

Valproate-Specific Toxicities

Before starting valproate, obtain: liver function tests, complete blood count, pregnancy test 1

Monitor every 3-6 months: serum drug levels, hepatic indices, hematological indices 1

Critical warning: Valproate is associated with polycystic ovary disease in females—counsel all female patients about this risk 1.

Cardiac Arrhythmia Risk

Antipsychotics (both typical and atypical) increase sudden cardiac death risk dose-dependently, with adjusted incidence-rate ratios from 1.59 to 2.86 for atypical agents 3. Baseline and follow-up ECGs are warranted in patients with cardiac risk factors or those on high doses.

Disease-Related Risks

Suicide (Most Lethal Outcome)

The annual suicide rate is 0.9% in bipolar disorder versus 0.014% in the general population—a 64-fold increase. Approximately 15-20% of bipolar patients die by suicide 2. This risk persists throughout the illness and requires continuous assessment at every visit.

Mood Episode Relapse

Over 80% of patients experience at least one relapse, with over 90% of medication-nonadherent adolescents relapsing within 18 months. 1 The median time to relapse after switching from combination therapy to monotherapy is only 3 months 1.

Educate patients and families to recognize early warning signs:

  • Sleep disruption (first indicator of impending mania)
  • Increased energy or decreased need for sleep
  • Emerging depressive symptoms
  • Substance use (45% smoking rate in bipolar patients) 2

Sleep disturbances specifically predict poorer functional outcomes and should trigger immediate intervention 4.

Treatment Nonadherence

More than 50% of bipolar patients are nonadherent to treatment 2. Nonadherence is the single largest modifiable risk factor for relapse. Monitor medication-taking through appointment-keeping, patient self-reports, plasma drug levels, and involvement of significant others 5.

Extrapyramidal Side Effects

Tardive dyskinesia and other extrapyramidal symptoms occur with atypical antipsychotics and require ongoing monitoring using standardized movement disorder scales 1.

Common Pitfalls to Avoid

  1. Periodic lab monitoring alone is insufficient—educate patients about presenting symptoms of adverse effects, as laboratory abnormalities may develop between scheduled tests 1

  2. Don't assume atypical antipsychotics are metabolically safe—they carry similar or greater metabolic risk than older agents and require the same rigorous monitoring 1

  3. Antidepressant monotherapy destabilizes mood—antidepressants may precipitate mania or rapid cycling and should only be used with concurrent mood stabilizers 1

  4. Gradual medication discontinuation is mandatory—abrupt lithium withdrawal dramatically increases relapse risk, especially within 6 months 1

  5. Weight gain is not cosmetic—it directly increases mortality and must be addressed aggressively with dietary intervention and exercise programs from treatment initiation 1, 6

References

1
Guideline

practice parameter for the assessment and treatment of children and adolescents with bipolar disorder.

Journal of the American Academy of Child and Adolescent Psychiatry, 2007

5
Research

Strategies for monitoring outcomes in patients with bipolar disorder.

Primary care companion to the Journal of clinical psychiatry, 2010

Related Questions

What is the laboratory workup for bipolar disorder?
How should I manage a manic bipolar patient who is non‑adherent with medication, currently taking cariprazine (Vraylar) 4.5 mg, and I am trying to obtain voluntary admission?
In a 43-year-old patient with bipolar disorder presenting with persistent left groin pain, what is the appropriate evaluation and management?
What is the appropriate next step in management for a 61-year-old woman with bipolar II disorder, a history of drug use in remission, currently taking quetiapine (Seroquel) 300 mg at bedtime, who reports a persistent low mood without the typical cycling?
What is the best mood stabilizer for a 52-year-old female resident with bipolar disorder who cycles between hypomania and mild depressive episodes?
How should I administer and score the Mood Disorder Questionnaire (MDQ) for an adult patient currently being treated for depression?
What are the pharmacological treatment options for schizoaffective disorder?
In an adult patient with urosepsis who has recently received meropenem, what empiric antimicrobial therapy should be initiated?
Is it appropriate to initiate an SGLT2 inhibitor in an 87-year-old patient after coronary artery bypass graft surgery?
What signs of bipolar disorder should be monitored in primary care?
What simple screening questions can I ask in a primary care office to assess for bipolar disorder?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.